Build my stack

Cagrilintide Peptide Dosage Chart: Trial Doses, Syringe Units and CagriSema Results

Ready to buy? the vendor scorecard ranks every seller we review on lab tests, shipping and price, with reader codes.
Disclosure: affiliate links below may earn the Bureau a commission at no cost to you.

The short answer

Cagrilintide has no approved dose. Phase 2 tested 0.3, 0.6, 1.2, 2.4 and 4.5 mg once weekly; phase 3 uses 2.4 mg, alone or with semaglutide (CagriSema). A 10 mg vial in 2 mL of bacteriostatic water gives 5 mg/mL: 0.3 mg is 6 units on a U-100 syringe, 2.4 mg is 48 and 4.5 mg is 90. Jump to the chart.

Best vendor for cagrilintide right now: Amino Club, Code 100: 20% off.

Check price at Amino ClubNot sure what to get? Match me in 60 secondsBlack Friday 40% off, applied by our link (was 20%) code 100 ends 30 Nov

Bureau Score 4.7, 0 of 1 independent tests passed (Finnrick). Compare every store. Reader codes were checked on the vendor's cart; offer terms are the vendor's and can change. Affiliate link: we earn a commission if you order. Laboratory research use only, not for human use.

Research context: Cagrilintide is an unapproved investigational compound currently in Phase 3 clinical trials. It is not FDA-approved for any indication and is available only as a research compound for laboratory use. Everything below describes clinical trial findings and research-community protocols. This is not medical advice and should not be used to guide treatment of any condition.

Quick facts

Also known as
NNC0174-0833 (Novo Nordisk development code)
Classification
Long-acting amylin analogue
Primary mechanism
Amylin receptor (AMY1-3), calcitonin receptor, satiety signalling
Complementary pathway
Amylin and calcitonin receptor agonist; separate receptor pathway from GLP-1
Administration
Subcutaneous injection, once weekly
Trial maintenance dose
2.4 mg weekly
Phase 2 doses (cagrilintide alone)
Phase 2 tested fixed doses of 0.3, 0.6, 1.2, 2.4 or 4.5 mg weekly, each reached after an escalation of up to 6 weeks
CagriSema escalation
2.4 mg of each, reached after a 16-week escalation (REDEFINE 1)
Half-life
Roughly 7 to 8 days, which is what makes weekly dosing work
Combination compound
CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg)
REDEFINE 1 weight loss
-20.4% at 68 weeks vs -3.0% on placebo (CagriSema)
Development stage
Phase 3; CagriSema submitted to the FDA December 2025, no decision found by 8 November 2026

The cagrilintide peptide is the compound that gets discussed alongside semaglutide and tirzepatide but works through a completely different pathway. Every major weight-loss agent of the past five years has been a GLP-1 receptor agonist or a multi-incretin approach layered on top of GLP-1. Cagrilintide is an amylin analogue, meaning it mimics a different pancreatic hormone entirely. It does not compete with semaglutide. It pairs with it.

That pairing is called CagriSema: a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg in a single weekly subcutaneous injection. The REDEFINE Phase 3 trial program positioned CagriSema against the best weight-loss numbers the GLP-1 class had produced, and the results were competitive with the top of that range. The research community is paying attention, and so are the people who have exhausted the current GLP-1 options and want to understand what comes next.

What cagrilintide actually does

Our top-scored source right now: Amino Club

The vendor Bureau readers order from most this year, with a batch COA on every product page. Partner code 100 at checkout takes 20% off there, and keeps the order counted for the Bureau. Research use only.

Visit Amino Club Compare all vendors Black Friday 40% off, applied by our link (was 20%) code 100 ends 30 Nov

Amylin is a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells. Its job is to modulate what happens after a meal. It slows gastric emptying, which extends the window of food absorption and blunts the post-meal glucose spike. It acts on the area postrema and hypothalamus to signal satiety and reduce further food intake. And it suppresses glucagon secretion, which helps prevent the liver from releasing glucose when blood glucose is already elevated.

Native amylin has a problem as a therapeutic: it aggregates readily and forms amyloid fibrils, which is not a property you want in an injectable compound. Pramlintide, the first synthetic amylin analogue, solved this by substituting three amino acids, but it is injected before each major meal, which limits real-world use considerably. Cagrilintide takes a different engineering approach. It is fatty-acid acylated to extend its half-life to roughly one week, similar to the engineering behind semaglutide versus liraglutide. That single-weekly-dose profile is what makes it practical to combine with once-weekly semaglutide.

The mechanism difference from GLP-1 matters because weight loss on GLP-1 receptor agonists levels off for many people. Amylin receptor pathways are a genuinely separate signal. In REDEFINE 1 the combination lost more weight than either drug alone, though less than the two effects added together.

CagriSema trial results

REDEFINE 1: the headline numbers

REDEFINE 1 was the pivotal phase 3 trial in adults without diabetes who had a BMI of 30 or more, or 27 or more with an obesity-related condition. It randomised 3,417 people to cagrilintide 2.4 mg plus semaglutide 2.4 mg, either drug alone, or placebo for 68 weeks, with a 16-week escalation. Mean body weight fell 20.4 percent on the combination against 3.0 percent on placebo, a difference of 17.3 points (treatment-policy estimand). Gastrointestinal adverse events affected 79.6 percent on the combination and 39.9 percent on placebo, mostly transient and mild to moderate (NEJM 2025).

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Those numbers put CagriSema roughly in the same territory as the top end of the tirzepatide dose range (approximately 20 to 22 percent at 15 mg) and competitive with early Phase 2 retatrutide data. The important distinction is pathway: CagriSema works through GLP-1 plus amylin rather than GLP-1 plus GIP plus glucagon. The one direct comparison went against it: in the open-label REDEFINE 4 trial CagriSema did not meet its goal of non-inferiority to tirzepatide 15 mg at 84 weeks, 20.2 percent against 23.6 percent on the treatment-regimen estimand (Novo Nordisk, 23 February 2026).

REDEFINE 2: type 2 diabetes population

REDEFINE 2 enrolled 1,206 adults with type 2 diabetes, a BMI of 27 or more and an HbA1c of 7 to 10 percent. After 68 weeks body weight was down 13.7 percent on cagrilintide-semaglutide (2.4 mg each) against 3.4 percent on placebo, and 73.5 percent reached an HbA1c of 6.5 percent or less against 15.9 percent (NEJM 2025). Smaller weight loss in people with type 2 diabetes is the usual pattern for this drug class.

Cagrilintide as monotherapy

In the phase 2 trial, weight fell 6.0 to 10.8 percent at 26 weeks across the 0.3 to 4.5 mg doses, against 3.0 percent on placebo, and the 4.5 mg dose beat liraglutide 3.0 mg (10.8 against 9.0 percent) (Lancet 2021). That is a meaningful result for a single compound on a non-GLP-1 pathway, but the reason cagrilintide is genuinely interesting is the combination, not the monotherapy. The combination (20.4 percent) beat each component alone (14.9 percent on semaglutide, 11.5 percent on cagrilintide, against 3.0 percent on placebo, treatment-policy estimand), by less than the two effects added together.

Get the Dispatch

One research note, one vendor deal, once a week. Free dosing guide on confirm.

Double opt-in. Unsubscribe with one click. Research use only.

Cagrilintide dosage chart

Two sets of numbers circulate under the same name. The phase 2 dose-finding trial gave each group one fixed weekly dose, 0.3, 0.6, 1.2, 2.4 or 4.5 mg, reached after an escalation of up to 6 weeks, and ran for 26 weeks (NCT03856047). It was not a ladder in which one person climbed every rung. Phase 3 settled on 2.4 mg, given alone or with semaglutide 2.4 mg as CagriSema, reached after a 16-week escalation (NCT05567796). The chart shows each trial dose and what it reads on a syringe. Updated 8 November 2026.

Calculate your draw for cagrilintide

Enter the vial strength, the bacteriostatic water you added and your dose, and get the exact mark on the syringe. Free, no signup, and the result comes with a link you can share or save.

Open the cagrilintide calculator peptulator.com, the Bureau's independent tool
Cagrilintide dosage chart: the trial doses, 10 mg vial in 2 mL of bacteriostatic water (5 mg/mL)
DoseDrawU-100 syringe unitsFrequencyIn the trials
0.3 mg0.06 mL6 unitsOnce weeklyLowest phase 2 dose
0.6 mg0.12 mL12 unitsOnce weeklyPhase 2 dose
1.2 mg0.24 mL24 unitsOnce weeklyPhase 2 dose
2.4 mg0.48 mL48 unitsOnce weeklyPhase 2 dose, and the phase 3 dose in REDEFINE 1 and 2, alone or with semaglutide 2.4 mg
4.5 mg0.90 mL90 unitsOnce weeklyHighest phase 2 dose: 10.8 percent weight loss at 26 weeks, against 9.0 percent on liraglutide 3.0 mg
CagriSema escalation for comparison: 16 weeks to 2.4 mg of each component in REDEFINE 1. Those figures belong to the combination, not to a cagrilintide vial.

The unit column assumes the setup the cagrilintide calculator uses by default, a 10 mg vial reconstituted with 2 mL of bacteriostatic water, giving 5 mg/mL on a U-100 insulin syringe where 100 units is 1 mL. Change the water and every unit figure changes with it while the dose stays the same. The phase 2 range, 0.3 to 4.5 mg weekly, is 6 to 90 units at 5 mg/mL.

The same 0.3 mg starting dose at other vial and water combinations
Vial BAC water Concentration Draw for 0.3 mg U-100 units Doses per vial
10 mg1 mL10 mg/mL0.03 mL3 units33
10 mg2 mL5 mg/mL0.06 mL6 units33
10 mg3 mL3.33 mg/mL0.09 mL9 units33
20 mg1 mL20 mg/mL0.015 mL1.5 units66
20 mg2 mL10 mg/mL0.03 mL3 units66
20 mg3 mL6.67 mg/mL0.045 mL4.5 units66

If the draw is awkward to read, change the water rather than the dose. A 1.5 unit mark on a U-100 barrel is a guess; 6 units is a line you can see. That is the whole reason 2 mL is the default on the calculator.

Injection technique. Subcutaneous, typically abdomen, thigh, or upper arm. Rotate sites each week. Standard insulin-syringe or pen technique. The reconstitution and injection protocols are the same as for any lyophilised research peptide. The injection guide covers the mechanics, and the reconstitution guide handles the prep steps.

No approved dose. Cagrilintide is still in Phase 3 trials and has no FDA-approved dosing. The above reflects what trial protocols used, not a clinical recommendation.

Cagrilintide dosage with tirzepatide

This is one of the most searched questions about the compound and it has no trial behind it, so the honest structure of the answer is: here is why people ask, and here is what is actually known.

The reason people ask is straightforward. Tirzepatide is among the strongest approved weight management compounds, and weight loss on it eventually levels off. Cagrilintide acts on amylin receptors and the calcitonin receptor instead, which is a separate signal. So someone stalled on 10 or 15 mg of tirzepatide looks at adding an amylin analogue rather than pushing the incretin higher. Mechanistically that is the same logic CagriSema is built on, with a different GLP-1 in the other half.

What does not exist is data. No trial has combined cagrilintide with tirzepatide, and none is registered on ClinicalTrials.gov. The two compounds belong to competing companies: Novo Nordisk pairs its amylin analogue with its own semaglutide, and Lilly, which makes tirzepatide, has its own, eloralintide, in phase 3 alone and in combination with tirzepatide. Zealand Pharma's petrelintide, partnered with Roche, is also in phase 3. So the combination people are asking about is a community practice built on a plausible mechanism, not a studied protocol, and nothing here should be read as a recommendation to run it.

What can be said without a trial is short:

  • No dose exists for the pair. The doses in the chart above come from trials of cagrilintide alone or with semaglutide. None of them was tested with tirzepatide.
  • The gut is the obvious unknown. Both compounds slow gastric emptying, and gastrointestinal events were the most common adverse events in REDEFINE 1, which escalated over 16 weeks. How the two behave together has not been measured.

Research use only. Cagrilintide is investigational, tirzepatide outside a prescription is unapproved use, and combining two compounds that both slow gastric motility is not something the published literature covers.

Cagrilintide vs tirzepatide vs retatrutide

Tirzepatide

GLP-1 plus GIP dual agonist. Approximately 20 to 22 percent weight loss at 15 mg weekly (SURMOUNT trials). Available as Mounjaro and Zepbound. The current approved benchmark for this category. See our tirzepatide dosage guide for the full picture.

Retatrutide

GLP-1, GIP, and glucagon triple agonist. Phase 2 data showed up to 24 percent at 12 mg weekly, the highest number in the class from a single compound trial at the time. Still in late-stage development. See the retatrutide guide for trial data breakdown.

Where does cagrilintide fit? As monotherapy it does not match these numbers, but that is not the intended use. CagriSema reached 20.4 percent in REDEFINE 1 by adding an amylin pathway that does not overlap with GLP-1 mechanisms to semaglutide. For someone who has hit a plateau on semaglutide alone, adding an amylin-pathway compound represents a genuinely different option rather than a dose escalation of the same mechanism.

The deeper comparison question is whether CagriSema eventually competes with tirzepatide and retatrutide as an approved product, or whether it finds a more specific position in patients who are GLP-1 partial responders. That answer depends on the FDA's decision and the remaining phase 3 trials, neither of which is resolved as of November 2026. The tirzepatide vs retatrutide comparison covers the approved-vs-pipeline framing in more depth.

How the amylin pathway complements GLP-1

GLP-1 receptor agonists work primarily through appetite suppression driven by hypothalamic signalling and a degree of gastric motility reduction. The appetite suppression effect is real and accounts for most of the weight loss. Weight loss on these drugs typically levels off after several months of stable dosing.

Amylin does not signal through GLP-1 receptors. It acts through AMY1-3 receptors (combinations of calcitonin receptor with receptor activity-modifying proteins) and through direct area postrema signalling. The satiety signal is distinct in origin, which is the mechanistic reason why combining the two produces more effect than either alone. The gastric emptying delay from amylin adds to the GLP-1 mechanism rather than duplicating it, extending the post-meal satiety window further than either compound manages individually.

This is also why comparing the efficacy of CagriSema to tirzepatide by weight-loss percentage alone is somewhat reductive. The glycaemic effects, the composition of weight lost, and the durability of the effect may differ in ways that 68-week trial data does not yet fully characterise.

Cagrilintide side effects

The side effect profile is predictable from the mechanism. GI effects dominate, particularly during escalation, and are broadly similar to what the GLP-1 class produces because the two compounds share gastric emptying as a downstream effect.

  • Nausea: The most commonly reported, peaking during escalation steps. Typically improves at each stable dose level before the next increase.
  • Vomiting: Less common than nausea but occurs, mostly while the dose is still rising.
  • Diarrhoea and constipation: Both appear in trial data. Gastric emptying changes can shift transit in either direction depending on individual baseline motility.
  • Injection site reactions: Redness, minor swelling, and mild discomfort at the injection site. Rotating locations resolves most injection-site reactions.
  • Headache and fatigue: Reported in a minority of participants, more common early in the escalation period.

The numbers from the trials: in REDEFINE 1, gastrointestinal adverse events affected 79.6 percent of people on cagrilintide-semaglutide against 39.9 percent on placebo, mostly transient and mild to moderate (NEJM 2025). In REDEFINE 2 the figures were 72.5 and 34.4 percent (NEJM 2025). With cagrilintide alone in phase 2, 41 to 63 percent across the doses reported gastrointestinal events against 32 percent on placebo (Lancet 2021). CagriSema's application is with the FDA; the Bureau found no decision by 8 November 2026.

Long-term cardiovascular outcomes data does not yet exist for cagrilintide. The REDEFINE cardiovascular outcomes trial is ongoing. For more on GI side effect management in this compound class, the semaglutide side effects guide covers the shared elements of the GLP-1 side effect profile in detail.

Research sourcing and quality

Cagrilintide is a more complex molecule than small peptides like KPV or BPC-157, and synthesis quality matters more as a result. Fatty-acid acylation is not a commodity process. A vendor cutting corners on the acylation step produces a compound with a significantly shorter half-life than it should have, which means the weekly dosing schedule would not behave as expected.

What to verify:

  • Certificate of analysis with HPLC purity at 98 percent or higher, matched to the specific lot number
  • Mass spectrometry confirming correct molecular weight (cagrilintide: approximately 4409 Da)
  • Confirmation that acylation is present and attached at the correct position
  • Sterility and endotoxin testing for injectable compounds
  • Third-party lab, not in-house self-certification

Storage follows standard lyophilised peptide rules: freezer for the powder, refrigerator after reconstitution, protected from light. The peptide storage guide covers stability windows in more detail.

Where the Bureau sources this

The vendors we rank highest on the 2026 scorecard. Amino Club is the one Bureau readers order from most; code 100 takes 20% off there. Research use only.

Amino Club PSPeptides Limitless Life Peptides Checkout paused since 20 Nov 2026; the store says orders reopen soon.Black Friday 40% off, applied by our link (was 20%) code 100 ends 30 Nov

Frequently asked questions

What is cagrilintide?

Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk (NNC0174-0833). It mimics amylin, a hormone co-secreted with insulin that slows gastric emptying and signals satiety to the brain. Unlike GLP-1 receptor agonists, it acts primarily through amylin receptors and the calcitonin receptor. It is administered once weekly by subcutaneous injection and is currently in Phase 3 clinical trials as a standalone and in combination with semaglutide 2.4 mg (CagriSema).

What is CagriSema and what results has it shown?

CagriSema is the fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg in a single weekly injection. In the REDEFINE 1 phase 3 trial, mean body weight fell 20.4 percent at 68 weeks on the combination against 3.0 percent on placebo. This is the most clinically meaningful result from the compound: the combination exceeds what either component achieves alone, though by less than the two effects added together.

What is the cagrilintide dosage protocol?

Two protocols exist and they belong to different trials. In the 26-week phase 2 trial each group was given one fixed weekly dose, 0.3, 0.6, 1.2, 2.4 or 4.5 mg, reached after an escalation of up to 6 weeks. Phase 3 (REDEFINE 1 and 2) uses 2.4 mg of cagrilintide, alone or with semaglutide 2.4 mg, reached after a 16-week escalation. Because cagrilintide is still in Phase 3 development there is no approved clinical dose, and both ladders are descriptions of trial protocols rather than recommendations.

How many units is 0.3 mg of cagrilintide?

It depends entirely on the water. In a 10 mg vial reconstituted with 2 mL the concentration is 5 mg/mL, so 0.3 mg is 0.06 mL, which is 6 units on a U-100 insulin syringe. The same vial with 1 mL of water makes it 3 units and with 3 mL it makes it 9 units. The dose has not changed in any of those, only the mark. The cagrilintide calculator runs it for any combination.

What is the cagrilintide dosage with tirzepatide?

There is no studied answer, because no trial has combined them. There is no dose to give for the pair. Both slow gastric emptying, and gastrointestinal events were the most common adverse events in the trials of each, so the combination's effect on the gut is the obvious unknown.

How does cagrilintide compare to tirzepatide and retatrutide?

Tirzepatide is a GLP-1 and GIP dual agonist achieving roughly 20 to 22 percent weight loss. Retatrutide is a GLP-1, GIP, and glucagon triple agonist with Phase 2 data showing up to 24 percent weight loss. CagriSema reaches a similar range via a completely different pathway: GLP-1 plus amylin rather than multiple incretin receptors. The compounds are not directly comparable because they differ by mechanism, not just potency. Cagrilintide is most relevant for GLP-1 partial responders or as a next step after semaglutide.

What are cagrilintide side effects?

The profile resembles GLP-1 receptor agonists: nausea, vomiting, diarrhoea, constipation, and injection site reactions are most common, peaking during escalation and settling at maintenance.

Is cagrilintide available for research use?

Cagrilintide is not FDA-approved and is sold as a research compound for laboratory use only. It is available from select research peptide vendors with verified third-party tested material. As with all research-use compounds, purchasing and using cagrilintide outside of an approved clinical trial carries regulatory and safety uncertainties that differ by jurisdiction.

Can cagrilintide be used without semaglutide?

Phase 2 monotherapy data showed 10.8 percent weight loss at 26 weeks on the top 4.5 mg weekly dose, against 3.0 percent on placebo, which is meaningful but well below the combination results. The compound was designed with combination use in mind, and the clinical development program reflects that. Standalone use is studied and not impossible, but the combination is what the Phase 3 program is built around.

Sources (checked 7 November 2026)

  1. Lau DCW et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet 2021;398:2160-2172
  2. Garvey WT et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med 2025;393:635-647
  3. Davies MJ et al. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes (REDEFINE 2). N Engl J Med 2025;393:648-659
  4. ClinicalTrials.gov NCT03856047, phase 2 dose-finding trial record (fixed-dose arms, 26 weeks)
  5. ClinicalTrials.gov NCT05567796, REDEFINE 1 record (16-week dose escalation)
PB
The Peptide Bureau editorial desk. Peptide Bureau is a small independent research team covering peptide dosing, safety and vendors. We are not clinicians; nothing here is medical advice. How the Bureau works.

Which peptide research protocol fits you?

Five questions, about 30 seconds. You get the dose per shot, the cycle length, the monthly cost and the tested vendor we would order from. Research use only.

Build my stack

Related on Peptide Bureau

See mazdutide.